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ABSTRACT
Current antipsychotics are effective in treating the positive symp-
toms associatedwith schizophrenia, but they remain suboptimal in
targeting cognitive dysfunction. Recent studies have suggested
that positive allosteric modulation of the M1 muscarinic acetylcho-
line receptor (mAChR) may provide a novel means of improving
cognition. However, very little is known about the potential of
combination therapies in extending coverage across schizo-
phrenic symptom domains. This study investigated the effect of
theM1mAChR positive allosteric modulator BQCA [1-(4-methoxy-
benzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid], alone or
in combination with haloperidol (a first-generation antipsy-
chotic), clozapine (a second-generation atypical antipsychotic), or
aripiprazole (a third-generation atypical antipsychotic), in reversing
deficits in sensorimotor gating and spatial memory induced by
the N-methyl-D-aspartate receptor antagonist, MK-801 [(5R,10S)-
(1)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-
imine]. Sensorimotor gating and spatial memory induction are
two models that represent aspects of schizophrenia modeled in
rodents. In prepulse inhibition (an operational measure of senso-
rimotor gating), BQCA alone had minimal effects but exhibited
different levels of efficacy in reversing MK-801–induced prepulse
inhibition disruptions when combined with a subeffective dose of
each of the three (currently prescribed) antipsychotics. Further-
more, the combined effect of BQCA and clozapine was absent in
M1
2/2 mice. Interestingly, although BQCA alone had no effect in
reversing MK-801–induced memory impairments in a Y-maze
spatial test, we observed a reversal upon the combination of
BQCA with atypical antipsychotics, but not with haloperidol.
These findings provide proof of concept that a judicious combi-
nation of existing antipsychotics with a selective M1 mAChR
positive allosteric modulator can extend antipsychotic efficacy in
glutamatergic deficit models of behavior.
Introduction
Schizophrenia affects approximately 1% of the population
and is characterized by positive, negative, and cognitive
symptoms (Pantelis et al., 1997, 1999, 2001; Grube et al.,
1998; Harvey et al., 1998; Heinrichs and Zakzanis, 1998;
Kandel, 2000; Bora et al., 2009). Current antipsychotics are
generally successful in treating the positive symptoms (e.g.,
hallucinations and delusions) but remain largely ineffective in
relieving negative and cognitive symptoms and also possess
side effects (Speller et al., 1997; Pantelis and Lambert, 2003;
Lieberman et al., 2005; Keefe et al., 2007; Gao et al., 2008;
Nasrallah, 2008; Sakurai et al., 2013). Hence, there is an
unmet need for newer approaches that could target additional
symptom domains and produce fewer side effects.
Existing antipsychotics treat positive schizophrenic symp-
toms by targeting the dopamine system, particularly the
D2 receptor (Conn et al., 2008; Miyamoto et al., 2012). The
broader, poorly treated, negative and cognitive domains
involve additional pharmacological targets. Glutamatergic
neurotransmission, in particular that mediated by the
N-methyl-D-aspartate receptor (NMDAR), is potentially one
such target (Rujescu et al., 2006; Javitt, 2007; Stone et al.,
2007; Gordon, 2010). NMDAR antagonists, such as phencycli-
dine, produce psychotic-like symptoms in humans (Javitt and
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Zukin, 1991; Murray, 2002; Moghaddam and Javitt, 2012).
Subanesthetic doses of MK-801 [(5R,10S)-(1)-5-methyl-10,11-
dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine], a more po-
tent NMDAR antagonist, also induce animal behaviors that
resemble aspects of schizophrenia, such as deficits of gating
mechanisms and spatial memory (Bubeníková et al., 2005;
Long et al., 2006; Bradford et al., 2010; van der Staay et al.,
2011; Bubser et al., 2014). Accordingly, the ability of novel
compounds to reduceMK-801–induced behaviors is commonly
used as part of a battery of tests that assess preclinical
utility of investigational molecules as potential antipsychotics
(Enomoto et al., 2008; Bubser et al., 2014; Park et al., 2014).
Muscarinic acetylcholine receptors (mAChRs), in particular
central M1 and M4 mAChRs, are implicated in learning and
memory and have been pursued as therapeutic targets for
cognitive dysfunction, including in schizophrenia (Langmead
et al., 2008; Lieberman et al., 2008). Furthermore, cholinergic
and dopaminergic networks can interact with one another
(Lester et al., 2010). For example, stimulation of mAChRs
in the ventral tegmental area increases dopamine release in
the striatum and frontal cortex (Gronier et al., 2000), and
knockout of M1 mAChRs increases striatal dopamine levels
(Gerber et al., 2001). Importantly, the cholinergic system also
interacts with glutamatergic transmission; M1 mAChRs mod-
ulate NMDAR current in hippocampal neurons (Jones et al.,
2008). Of note, xanomeline, an M1 and M4 mAChR-preferring
agonist, improved psychotic symptoms in patients with Alz-
heimer disease and cognitive function in people with schizo-
phrenia (Bodick et al., 1997; Shekhar et al., 2008). However,
further clinical development of xanomeline was precluded due
to unacceptable side effects, predominantly reflecting off-
target activity via the highly conserved orthosteric site at
other mAChR subtypes (Bodick et al., 1997; Wood et al., 1999;
Bymaster et al., 2002). Encouragingly, mAChRs possess
spatially distinct allosteric sites that offer alternative strate-
gies for greater selectivity (Christopoulos, 2002; Bridges et al.,
2010; Bolbecker and Shekhar, 2012; Conn et al., 2014; Kruse
et al., 2014; Thal et al., 2016). BQCA [1-(4-methoxybenzyl)-4-
oxo-1,4-dihydroquinoline-3-carboxylic acid], a highly selec-
tive M1 mAChR positive allosteric modulator (PAM) with no
reported off-target activities, reversed scopolamine-disrupted
memory, rescuedmemory deficits in amousemodel of Alzheimer
disease, and also had procognitive effects on baseline memory
performance (Ma et al., 2009; Shirey et al., 2009; Chambon et al.,
2011, 2012; Galloway et al., 2014). The effects may be due to
activation of neurons in the prefrontal cortex and hippocampus,
as these regions express high levels ofM1mAChRs (Porter et al.,
2002; Ma et al., 2009).
The superior efficacy of existing atypical antipsychotics may
be related to their complex polypharmacology (Miyamoto
et al., 2005). However, less is known about the potential of
combination therapies for improved treatment of negative and
cognitive schizophrenic domains. Most atypical antipsychotics
have limited affinity for the M1 mAChR; however, a few (e.g.,
clozapine and olanzapine) are antagonists at the M1 mAChR,
an action linked to acute memory impairment (Bymaster
et al., 1999; Didriksen et al., 2006; Mutlu et al., 2011;
Miyamoto et al., 2012). Hence, coadministration of a com-
pound that could specifically activate or potentiate the M1
mAChR together with select current antipsychotics may offer
additional therapeutic value in extending antipsychotic effi-
cacy. This study thus aimed to investigate the effects of a
combination of BQCA with selected typical and atypical
antipsychotics on MK-801–induced behaviors in mice, specif-
ically prepulse inhibition (PPI) disruption and impaired
memory in the Y-maze spatial test.
Materials and Methods
Materials. Chinese hamster ovary (CHO)FlpIn cells andDulbecco’s
modified Eagle’s medium were purchased from Invitrogen (Carlsbad,
CA). Fetal bovine serum was purchased from ThermoTrace (Mel-
bourne, Australia). Hygromycin-B was purchased from Roche (Man-
nheim, Germany). N-[3H] methylscopolamine ([3H]NMS; specific
activity, 85 Ci/mmol) and Ultima gold scintillation liquid were
purchased from PerkinElmer Life Sciences (Boston, MA). BQCA,
clozapine, and aripiprazole were synthesized in-house, and all other
chemicals were purchased from Sigma-Aldrich (St. Louis, MO). FlpIn
CHO cells stably expressing the human M1 mAChR were generated
and maintained as described previously (Abdul-Ridha et al., 2014).
In Vitro Competition Binding Assays. FlpInCHOcells express-
ing thehumanM1mAChRwere platedat25,000 cells perwell in 96-well
Isoplates (PerkinElmer Life Sciences). The next day, cells were in-
cubated in a final volume of 100 ml HEPES buffer (10 mM HEPES,
145 mM NaCl, 1 mM MgSO4×7H2O, 10 mM glucose, 5 mM KCl, 2 mM
CaCl2, and 1.5 mM NaHCO3, pH 7.4) containing increasing concentra-
tions of a competing cold ligand carbachol (in the absence or presence of
10 mMBQCA) in the presence of 0.1 nM [3H]NMS for 4 hours at 4°C (to
avoid potential confounding effects of competing agonist ligands on
receptor internalization while ensuring reactions reached equilibrium).
Nonspecific bindingwas defined in the presence of 100mMatropine. For
all experiments, termination of the assay was performed by rapid
removal of the radioligand followed by two 100-ml washes with ice-cold
0.9% NaCl buffer. Radioactivity was determined by addition of 100 ml
Microscint scintillation liquid (PerkinElmer Life Sciences) to each well
and counting in a MicroBeta plate reader (PerkinElmer Life Sciences).
Animals and Drugs. The experiments were performed using 2- to
4-month-old male C57Bl/6J, M1 mAChR homozygous knockout (M1
2/2),
and wild-type (M1
1/1) mice in accordance with the Australian Code
of Practice for the Care and Use of Animals for Scientific Purposes.
Behavioral testing procedures were approved by the Animal Ethics
Committee of the Monash Institute of Pharmaceutical Sciences. The
M1
2/2 mice, which were backcrossed to C57Bl/6N for more than
11 generations, and both M1
1/1 and M1
2/2 mice shared the same
C57Bl/6N background (Bymaster et al., 2003; Thomsen et al., 2010).
They were bred and genotyped at the Monash Institute of Pharma-
ceutical Sciences (Parkville, Australia). Mice were housed on a
reversed light/dark cycle (lights on 7 PM) with ad libitum access to
food andwater. As outlined in theResults and in Table 1, two different
routes of administration were used: C57Bl/6Jmice received BQCA via
subcutaneous injection, as per a previous study in this mouse strain
from our laboratory when investigating another class of mAChR PAM
(Suratman et al., 2011), and were tested in both PPI and Y-maze
behavioral tests. However, prior studies have shown that M1
1/1 and
M1
2/2 mice on a C57Bl/6N substrain background can exhibit a
different PPI profile (Matsuo et al., 2010) compared with C57Bl/6J
mice. Given the limited number of animals available for these latter
studies and our desire to maximize interanimal consistency, we
performed new pharmacokinetic studies that revealed that intraper-
itoneal injection of BQCA (in a solubilized formulation) resulted in
higher exposure in this instance (seeResults). BQCA (1–20mg/kg) was
suspended in a combination of 50% Pharmasolve (Ashland Inc.,
Bridgewater, NJ) and 1.1% Tween 20 (Sigma-Aldrich, Castle Hill,
Australia) in injection water (PLP, Glendenning, Australia) for sub-
cutaneous injection (Suratman et al., 2011), or dissolved in 15%
dimethylsulfoxide (DMSO) (Sigma-Aldrich), 2% Tween 20, and 22mM
Tris buffer (pH 8.9) for intraperitoneal injection. Together with BQCA
administration (subcutaneously or intraperitoneally), animals re-
ceived a single intraperitoneal dose of 0.03–0.25 mg/kg haloperidol
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(Tocris, Bristol, UK) (dissolved in 1% DMSO saline), 0.5–2 mg/kg
clozapine, or 2.5 mg/kg aripiprazole (dissolved in 2% Tween 20 saline).
Twenty-five minutes later, mice received an intraperitoneal injection
of 0.15 or 0.3 mg/kg MK-801 (Sigma-Aldrich) dissolved in 0.1%
ascorbic acid saline, and mice were then subjected to PPI or a
Y-maze training session (Ytrain) 20 minutes afterward (see Results
and figures for timelines). The doses of antipsychotics were specifically
chosen to be subeffective in the model under test, based on previous
studies (haloperidol; Bast et al., 2000), or pilot studies conducted
in-house (clozapine and aripiprazole). Our pilot study showed that
4 mg/kg clozapine, or 20 mg/kg aripiprazole, reversed PPI disruption
induced by 0.3 mg/kg MK-801. Haloperidol, at any doses below those
that cause catalepsy (i.e., ,0.5 mg/kg, above which catalepsy is
observed), was ineffective at reversing the MK-801 effect. In addition,
all antipsychotic doses used were either lower than (aripiprazole and
clozapine) or within (haloperidol) the clinically comparable rangewith
regard to their likely dopamine D2 receptor occupancies in humans
(Kapur et al., 2003; Natesan et al., 2011).
Assessment of BQCA Exposure. BQCA exposure was assessed
in three separate pharmacokinetic studies (see Results). Separate
groups of C57Bl/6J, M1
1/1, and M1
2/2 behavioral naïve mice were
administered BQCA (subcutaneously or intraperitoneally), with anti-
psychotics (2 mg/kg clozapine, 0.25 mg/kg haloperidol, or 2.5 mg/kg
aripiprazole), or vehicle and were euthanized at time points relevant
to the collection of behavioral data (i.e., 45, 90, or 180 minutes
postdose). Concentrations of BQCA or antipsychotics, in plasma and/
or brain homogenate, were determined via ultra-performance liquid
chromatography/mass spectrometry. The concentration of BQCA in
the brain parenchyma (Cbrain) was calculated on the basis of the
measured concentration in the brain homogenate (Cbrain homogenate),
after correcting for the contribution of compound contained within the
vascular space of brain samples as follows:
Cbrain 5 Cbrain homogenate 2 Cbrain vasculature, where Cbrain vasculature is
Cplasma  Vp.
Cbrain, Cbrain homogenate, and Cbrain vasculature are the concentrations of
compound in the brain parenchyma, brain homogenate, and brain
vasculature, respectively (in nanograms per gram). Cplasma is the
concentration of compound in plasma (in nanograms permilliliter). Vp
is the brain plasma volume (0.017 ml/g for C57Bl6 mice; Nicolazzo
et al., 2010).
The unbound concentration of BQCA (Cunbound) in the brain
parenchyma was then calculated as Ctotal  fu, using published
fraction free concentration (fu) values for BQCA (i.e., fu,brain 5 0.126;
Gould et al., 2015). Otherwise, the total concentration of antipsy-
chotics (Ctotal) is presented. The data are expressed in nanomolar units
assuming a brain density of 1 g/ml.
TABLE 1
Experimental groups and reports of ANOVA analysis
Behavioral Test Mouse Strain No. of Mice Drugs (Route)
Main Effects and Interactions after ANOVA Analysis
Cohort F Value P Value
PPI C57Bl/6J Vehicle and MK-801
controls, 15–17; others,
9–10
BQCA (s.c.) +
antipsychotics
(i.p.)
MK-801 overall F(1, 343) = 315.3 ,0.001
BQCA alone None
BQCA + haloperidol
BQCA effect F(4, 174) = 4.3 0.002
Haloperidol effect F(1, 174) = 45.0 ,0.001
BQCA  haloperidol
interaction
F(4, 174) = 3.3 0.013
BQCA + clozapine
BQCA effect F(4, 165) = 2.7 0.032
Clozapine effect F(1, 165) = 31.6 ,0.001
BQCA + aripiprazole
BQCA effect F(4, 160) = 2.7 0.031
Aripiprazole effect F(1, 160) = 24.6 ,0.001
Prepulses  BQCA 
Aripiprazole 
MK-801 interaction
F(4, 320) = 4.5 0.002
Y-maze C57Bl/6J 10–13 BQCA (s.c.) +
antipsychotics
(i.p.)
BQCA alone
Arm effect F(1, 59) = 17.2 ,0.001
Arm  MK-801 effect F(1, 59) = 9.7 0.003
BQCA + haloperidol
Arm effect F(1, 124) = 8.4 0.005
Arm  MK-801 effect F(1, 124) = 6.4 0.012
BQCA + clozapine
Arm effect F(1, 123) = 13.4 ,0.001
Arm  MK-801 effect F(1, 123) = 5.1 0.026
Arm  BQCA effect F(2, 123) = 3.5 0.034
BQCA + aripiprazole
Arm effect F(1, 132) = 18.0 ,0.001
Arm  MK-801 effect F(1, 132) = 8.6 0.004
PPI M1
+/+ mice (C57Bl/6 Ntac
background)
Vehicle and MK-801
controls, 15–16; others,
8–9
BQCA (i.p.) +
clozapine (i.p.)
M1
+/+ mice
M1
2/2 mice (C57Bl/6 Ntac
background)
Vehicle and MK-801
controls, 13–15; others, 8
MK-801 effect F(1, 67) = 29.0 ,0.001
BQCA effect F(2, 67) = 3.2 0.046
Clozapine effect F(1, 67) = 8.3 0.005
M1
2/2 mice
MK-801 effect F(1, 61) = 26.2 ,0.001
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PPI Test. PPI was performed in a sound-attenuated room using
SR-LAB startle chambers (San Diego Instruments, San Diego, CA).
Mice subjected to PPI testing received BQCA (1–20 mg/kg) with or
without antipsychotics, and then MK-801 (0.3 mg/kg) or its vehicle.
Each PPI session lasted for 1 hour and consisted of three startle pulses
(p100, p110, and p120) and was also preceded with 6-, 12-, and 18-db
prepulses above a 65-db background for each pulse (referred to as pp6,
pp12, and pp18, respectively), to provide a more comprehensive
characterization of PPI (Yee et al., 2005). In the first PPI study
conducted in C57Bl/6J mice, all treatment groups were pseudo-
randomized on each testing day, with at least one vehicle– and
MK-801–only treated mouse included as a control per PPI testing
day. There were 15–17 mice for the vehicle-only or MK-801–only
treatment groups, and there were 9–10 mice for all other treatment
groups. The second PPI study was conducted in bothM1
1/1 andM1
2/2
mice using the same PPI protocol, with 13–16 mice for the vehicle and
MK-801 controls and 8–9mice for the other treatment groups. In these
PPI studies, the drug effect on the overall PPI measured at the three
startle pulses (i.e., p100, p110, and p120) was found to be similar;
hence, only PPI data analysis obtained from p120 is reported. To
simplify data presentation, the average PPI (%) is presented in the
figures, and PPI (%) measured at each prepulse (pp6, pp12, and pp18)
is detailed in Table 2. There was no change to the startle response in
mice, except for those treated with the highest dose (20 mg/kg) of
BQCA alone (in the presence of MK-801) (Supplemental Fig. 1). The
averagePPI data of p100 andp110 are presented in Supplemental Fig. 2.
Y-Maze Test. Mice received BQCA, clozapine, haloperidol, aripi-
prazole, or a combination of BQCA and an antipsychotic before
MK-801 (0.15 mg/kg) injection. Since a lower dose of MK-801
(compared with 0.3 mg/kg used in PPI) was sufficient to disrupt
spatial memory formation in the Y-maze, the dose range of BQCA
chosen was also reduced to 5–10 mg/kg. The ranges of the antipsy-
chotics were also reduced relative to those used in the PPI studies:
haloperidol, 0.03 to 0.06 mg/kg; clozapine, 0.5 to 1 mg/kg;
and aripiprazole, 0.125 to 0.25 mg/kg. Higher doses of aripiprazole
(i.e., .0.25 mg/kg) were excluded, because mice had significantly
lower locomotor activity in both training and testing sessions. Y-maze
experiments were conducted in a manner similar to those previously
described with 10–13 mice per treatment group (Dellu et al., 1992;
Choy et al., 2008; Shipton et al., 2014). In brief, mice were allowed to
explore two arms, with the novel arm closed, in a training session
(Ytrain) that lasted for 10 minutes. Two hours later, the same mice
were allowed to explore all three arms for 5 minutes in the testing
session (Ytest). Behavior was recorded and analyzed with video
tracking software (Viewer III; Biobserve GmbH, Bonn, Germany),
and the time spent in each arm, during the testing session, was used
as a measure of the exploratory preferences of mice. A significant
difference between novel and familiar arms was considered as a
measure of baseline memory function. In a preliminary study, prior
to the full Y-maze test, MK-801 disrupted memory function when it
was administered before the training session rather than after (data
not shown). This finding is consistent with a previous study in which
MK-801 disrupted memory in a novel objection recognition test in
mice (Nilsson et al., 2007), suggesting that NMDARs blocked by
MK-801 disrupt memory acquisition during the training phase. The
Y-maze data of mice treated with the same vehicle used to
administer MK-801 (i.e., 0.1% ascorbic acid in saline) and a
combination of BQCA and antipsychotics are also reported in
Supplemental Fig. 3.
Data Analysis. For the in vitro studies, competition binding
parameters were determined via nonlinear regression as described
previously (Canals et al., 2012). All affinity values were estimated as
logarithms, and statistical comparisons between values were per-
formed by t tests using GraphPad Prism software (version 6.0;
GraphPad Software Inc., La Jolla, CA). Behavioral datawere analyzed
using IBM SPSS (version 22.0; IBM, Armonk, NY). PPI (%) was
analyzed with analysis of variance (ANOVA) with repeated measures
of prepulses (pp6, pp12, and pp18), with drug treatments as main
factors. Tukey’s post hoc test was then used to determine the level of
significance at each prepulse and average values of PPI (%) among
groups when there was a main drug effect or an interaction. For
Y-maze data, the time spent in novel and familiar arms is presented
(in seconds). If the overall main arm effect was significant in each
cohort, pairwise ANOVA comparisons were performed between the
TABLE 2
PPI measured with prepulses at 6, 12, and 18 db above the background in C57Bl/6J mice, which received
BQCA via the subcutaneous route
Data are presented as means 6 S.E.M.
Drug
PPI
pp6 pp12 pp18
%
Vehicle control 23.6 6 3.4 36.2 6 3.0 50.3 6 2.4
MK-801 23.0 6 3.2* 15.7 6 3.6* 17.4 6 2.5*
+ 1 mg/kg BQCA 1.1 6 5.1 12.1 6 4.7 17.5 6 6.8
+ 3 mg/kg BQCA 0.8 6 6.2 6.9 6 5.0 4.6 6 5.0
+ 10 mg/kg BQCA 1.4 6 5.7 11.1 6 6.0 21.4 6 6.1
+ 20 mg/kg BQCA 28.0 6 4.9 6.2 6 3.9 17.9 6 2.5
MK-801 + 0.25 mg/kg haloperidol 4.4 6 2.0 22.1 6 3.5 37.1 6 4.4
+ 1 mg/kg BQCA 6.2 6 3.6 18.8 6 3.1 35.6 6 2.9
+ 3 mg/kg BQCA 7.7 6 2.7 23.9 6 4.2 37.8 6 5.5
+ 10 mg/kg BQCA 10.9 6 2.9 23.7 6 3.5 36.9 6 4.4
+ 20 mg/kg BQCA 12.9 6 2.0 34.4 6 4.4 57.8 6 4.7**
MK-801 + 2 mg/kg clozapine 9.4 6 3.7 25.7 6 4.6 37.9 6 6.2
+ 1 mg/kg BQCA 8.4 6 2.6 16.7 6 2.8 36.3 6 4.2
+ 3 mg/kg BQCA 3.7 6 6.0 12.5 6 6.8 27.5 6 4.9
+ 10 mg/kg BQCA 0.2 6 3.8 22.4 6 4.4 38.0 6 4.4***
+ 20 mg/kg BQCA 14.0 6 8.0 32.6 6 4.7 56.4 6 4.9**
MK-801 + 2.5 mg/kg aripiprazole 8.2 6 3.2 20.7 6 3.5 27.7 6 4.3
+ 1 mg/kg BQCA 0.1 6 3.8 11.9 6 5.8 22.7 6 6.9
+ 3 mg/kg BQCA 23.6 6 5.2 14.4 6 4.2 30.3 6 3.9
+ 10 mg/kg BQCA 10.0 6 2.9 17.9 6 3.9 32.0 6 4.9
+ 20 mg/kg BQCA 3.9 6 4.5 26.2 6 5.2 47.0 6 3.1**
*P , 0.05 (versus vehicle control 2MK-801 effect); **P , 0.001 (versus MK-801 control at the same prepulse); ***P ,
0.05 (versus MK-801 control at the same prepulse).
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novel and familiar arms in each group. Both PPI and Y-maze data
analysis were divided into BQCA alone, BQCA plus haloperidol,
BQCA plus clozapine, and BQCA plus aripiprazole cohorts and
included their vehicle control in the ANOVA analysis. The drug effects
and interactions after the ANOVA analysis are reported in Table 1,
and post hoc tests are reported in the Results and/or indicated in the
figures. Data are presented asmeans6 S.E.M. A value ofP, 0.05was
considered statistically significant.
Results
BQCA, But Not Typical or Atypical Antipsychotics,
Acts as a PAM of Acetylcholine at the M1 mAChR.
BQCA is a highly selective PAM of acetylcholine (ACh) binding
and function at the M1 mAChR (Ma et al., 2009; Canals et al.,
2012). Therefore, any effect of BQCA in vivo is most likely
mediated by its interaction with the M1 mAChR. Nonetheless,
to ensure that there is no specific on-target allosteric interaction
between BQCA and the selected antipsychotics, we per-
formed competition-binding experiments using the radioligand
[3H]NMS on CHO FlpIn cells stably expressing the human M1
mAChR. As expected, clozapine displayed submicromolar affin-
ity for theM1mAChR (Ki5 0.3mM; Fig. 1A). In contrast, neither
haloperidol nor aripiprazole was able to fully inhibit [3H]NMS
binding, even at a concentration of 100 mM. Although 10 mM
BQCA caused a significant (60-fold) increase in ACh affinity, in
agreement with our previous findings (Abdul-Ridha et al., 2014),
BQCA had no effect on the affinity of clozapine (Fig. 1B); BQCA
also had no effect on haloperidol and aripiprazole (data not
shown). Therefore, BQCA does not modulate the binding of the
selected antipsychotics at the M1 mAChR.
Brain Exposure of BQCA. The apparent brain/plasma
ratio from our in vivo exposure study (data not shown) was
consistent with that observed previously (Ma et al., 2009;
Shirey et al., 2009; Gould et al., 2015). Also, there was a clear
dose-dependent increase in brain exposure in all cohorts ofmice
with BQCA administrated via subcutaneous or intraperitoneal
injection (Supplemental Fig. 4A). Of note, all C57Bl/6J mice
used in the behavioral studies reported in the main text
received BQCA via the subcutaneous route. In the last PPI
study using M1
1/1 and M1
2/2 mice (see below), the animals
received BQCA dissolved in DMSO-based vehicle via intraperi-
toneal injection, as in vivo exposure data indicated that this
method of administration resulted in higher overall exposure of
BQCA in this substrain (Supplemental Fig. 4B). Importantly, as
shown in Supplemental Fig. 4C, in no instance was the brain
exposure of either BQCA or any of the antipsychotics increased
whenmice were dosedwith both classes of compound. Therefore,
any observed behavioral effects of the combination are not a
result of increased exposure at their respective sites of action.
BQCA Alone Does Not Rescue MK-801–Induced
Disruptions in PPI. Themain effect ofMK-801 in all cohorts
of mice (Table 1) confirmed a significant PPI disruption in
MK-801–treated mice (Figs. 2 and 3). However, there was an
absence of a BQCA effect in the BQCA-alone cohort, suggesting
that BQCA alone did not have any substantial rescuing effects
on PPI disruption induced by MK-801 (Fig. 2B).
Combination of Subeffective Doses of BQCA with
Typical or Atypical Antipsychotics Produces Signifi-
cant Reversals in MK-801–Induced Disruptions in
PPI. As indicated in the Materials and Methods, the dose of
haloperidol (0.25 mg/kg) was specifically chosen from prior
studies to represent a subeffective dose level in the PPI
studies. In the BQCA plus haloperidol cohort, there was a
significant BQCA  haloperidol effect (Table 1) as an in-
dication of a synergistic effect between the two compounds.
Post hoc analysis (Table 2) showed that MK-801–induced
disruption in PPI was not fully reversed by either haloperidol
alone or a combination of haloperidol with 1–10 mg/kg BQCA.
However, a complete reversal of MK-801–induced PPI disrup-
tion was observed when the subeffective dose of haloperidol
was combined with 20 mg/kg BQCA (Fig. 3A). Similarly,
clozapine (2 mg/kg) alone and in combination with 1–10 mg/kg
BQCA failed to fully reverse MK-801–induced PPI disrup-
tion. However, a significant reversal was observed with the
combination of clozapine and BQCA (20 mg/kg) (Fig. 3B),
although there was an absence of BQCA by clozapine in-
teraction in the ANOVA, indicating that both BQCA and
clozapine were likely behaving additively rather than syn-
ergistically. Comparable trends were also observed in the
aripiprazole plus BQCA cohort, but only at the highest
prepulse tested (i.e., pp18) (Fig. 3C; Table 2). In this instance,
the significant prepulse by BQCA by aripiprazole interaction
(Table 1) indicated the presence of a synergistic effect of PPI
measured at pp18. Taken together, these results reveal that
Fig. 1. BQCA does not allosterically modulate antipsychotics at the M1
mAChR. (A) Antipsychotic affinity was measured at the human M1
mAChR stably expressed in CHO cells using competition binding
experiments with the antagonist [3H]NMS. Clozapine (pKB = 6.46 6
0.10) displayed significant affinity for the M1 mAChR. In contrast, even
at a maximal concentration of 100 mM, haloperidol and aripiprazole were
unable to completely displace [3H]NMS. (B) Competition binding studies
between ACh or clozapine with [3H]NMS were performed in the absence
(open bars) and presence (filled bars) of 10 mM BQCA. BQCA (10 mM)
caused a significant 60-fold increase in ACh affinity (P, 0.001, two-tailed
t test) but had no significant effect on the affinity of clozapine.
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BQCA enhanced subeffective doses of commonly used antipsy-
chotics to produce a rescue of PPI deficits in MK-801–treated
mice.
BQCA Enhanced the Rescuing Effect of Clozapine or
Aripiprazole, But Not That of Haloperidol, in the
Y-Maze Test. To explore memory performance, the duration
spent (in seconds) in novel and familiar arms for each
treatment group was analyzed (Table 1). There was a main
arm effect and a significant arm  MK-801 interaction,
indicating disruption of short-term memory in the Y-maze
test by MK-801 (Table 1). Further analysis revealed differ-
ences between the novel and familiar arms in vehicle-treated
mice (P 5 0.002; Fig. 4B). In MK-801–treated mice, pre-
treatment with 10 mg/kg BQCA and 1 mg/kg clozapine (P 5
0.007; Fig. 5B), or 5mg/kgBQCAand 0.125mg/kg aripiprazole
(P 5 0.026; Fig. 5C), also showed novel versus familiar arm
differences, which is indicative of normal memory function as
seen in vehicle control mice (Fig. 5). There were no differences
in the other treatment groups, including BQCA alone or in
combination with haloperidol (Fig. 5A). These results demon-
strate a synergistic effect between BQCA and the atypical
antipsychotics, clozapine or aripiprazole, on memory function,
which was not seen with BQCA on its own or in combination
with haloperidol, in this acute memory disruption model.
M1 mAChR Is Required for the Combined Effect of
BQCA and Clozapine in Reversing PPI Deficits. To
confirm the requirement of the M1 mAChR for the observed
combined effect, we repeated selected key BQCA and cloza-
pine interaction studies in mice lacking the M1 mAChR; this
also necessitated testing in different background mouse
strains. The combined effect between BQCA and clozapine
seen in reversing MK-801–induced PPI deficits was reproduc-
ible in C57Bl/6J mice using this administration method
(Supplemental Fig. 5). Moreover, consistent with previous
findings (Matsuo et al., 2010), we noted that both M1
1/1 and
M1
2/2mice on a C57Bl/6N background exhibited a higher PPI
compared with the C57Bl/6J mice used in the preceding
studies. PPI disruption was induced to a similar extent by
0.3 mg/kg MK-801 in both M1
1/1 and M1
2/2 mice. A partial,
Fig. 3. Combination of subeffective doses of BQCA and haloperidol or
clozapine can reverse MK-801–induced disruption in average PPI. (A and
B) Both haloperidol (0.25 mg/kg) and clozapine (2 mg/kg) did not reverse
MK-801–induced PPI disruption; however, the combination with BQCA
(20 mg/kg, s.c.) resulted in significant reversal of PPI disruption in C57Bl/
6Jmice. (C) The combination of BQCA (20mg/kg, s.c.) and aripiprazole did
not produce a reversal in average PPI, except PPI measured at pp18
(Table 2). *P , 0.05 (for difference with MK-801 post hoc comparisons);
**P, 0.001 (for difference with MK-801 post hoc comparisons); ^P, 0.05
(for significant MK-801–induced disruption). Data are presented as
means 6 S.E.M. (vehicle– and MK-801–only controls, n = 15–17, which
were reused in each cohort set, in this figure and in Fig. 2; and other
treatment groups, n = 9–10).
Fig. 2. BQCA alone has minimal effects on MK-801–induced disruptions
in PPI. (A) A timeline of drug treatment and PPI testing is presented.
MK-801 (0.3 mg/kg, i.p.) was administered 25 minutes after BQCA and
antipsychotics, and mice were subjected to PPI testing 20 minutes after
MK-801 treatment. (B) MK-801 (0.3 mg/kg, i.p.) induced significant PPI
disruption in C57Bl/6J mice. BQCA (0–20 mg/kg, s.c.) did not reverse the
MK-801–disrupted PPI. ^P , 0.05 (for significant MK-801– induced
disruption). Data are presented as means 6 S.E.M. (vehicle– and
MK-801–only controls, n = 15–17, which were reused in each cohort set,
in this figure and in Fig. 3; and other treatment groups, n = 9–10).
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but statistically nonsignificant, reversal of the PPI deficit was
observed after dosing clozapine alone, consistent with the
observation in C57Bl/6J mice (Fig. 6). A qualitatively similar
partial reversal was observed afterM1
1/1mice receivedBQCA
alone at 20 mg/kg, a trend that was not observed in C57Bl6J
mice. This reversal failed to achieve statistical significance
and was not observed in subsequent studies with further
cohorts of M1
1/1 mice. The most important finding, however,
was that MK-801–disrupted PPI was rescued by the combi-
nation of BQCA (20 mg/kg) and clozapine (3 mg/kg) in the
M1
1/1mice, and there was a complete absence of such rescue
in the M12/2 mice receiving the same treatment (Fig. 6;
Table 3). These results demonstrate the selectivity of BQCA
in vivo and also confirm that the M1 mAChR is required in
order to observe efficacy enhancement of clozapine actions.
Discussion
This study provides proof of concept that the combination of
an M1 mAChR PAM with different antipsychotic drugs can
yield synergistic (or additive) efficacy in two animal behavior-
al models that are considered to reflect aspects of schizophre-
nia. These effects are not mediated by on-target allosteric
interactions at the M1 mAChR between BQCA and the
antipsychotics, but activation of the receptor is necessary
because the interaction between BQCA and clozapine in
reversing MK-801–induced PPI disruption is lost in M1
2/2
mice. If these findings can be generalized to other aspects or
models of schizophrenia, then this may provide impetus for
future consideration of the use of M1 mAChR PAMs as
potential add-on therapies to selected existing drug regimens.
Haloperidol is a first-generation antipsychotic agent, repre-
sentative of the requirement for potent dopamine D2 receptor
antagonism in treating positive schizophrenic symptoms
(Mansbach et al., 1988; Conn et al., 2008; Miyamoto
et al., 2012). Clozapine was chosen as an atypical second-
generation antipsychotic with a broad polypharmacology
profile (Miyamoto et al., 2005; Nasrallah, 2008), whereas
aripiprazole was selected as a third-generation agent that
acts on D2 receptors as a partial agonist with a lower
propensity toward adverse metabolic side effects (Nasrallah,
2008; Cui et al., 2010). None of these drugs, however, are
effective at treating cognitive deficits associated with schizo-
phrenia (Lieberman et al., 2005; Lublin et al., 2005). However,
therapeutic targeting has not been limited to D2 receptors
(Conn et al., 2008; Owen et al., 2016). For example, agents
targeting mAChRs that are highly expressed in affected
Fig. 4. MK-801 induces spatial memory deficits in C57Bl/6J mice in the
Y-maze test. (A) A timeline of drug treatment and Y-maze testing is
presented. BQCA and antipsychotics were given 25 minutes prior to
MK-801 (0.15 mg/kg) administration, and the mice were then subjected to
a Y-maze training session 20 minutes after MK-801 treatment. The
retention period was 2 hours (between training [Ytrain] and testing [Ytest]
sessions). The duration spent (in seconds) in the novel and familiar arms
was used as the measure of memory function. (B) Analysis showed no
rescue of memory deficits induced by MK-801 (0.15 mg/kg) for mice
pretreated with BQCA alone. *P , 0.05 (for difference between the novel
and familiar arms as an indication of normal memory function). Data are
presented as means 6 S.E.M. (n = 10–13 mice per group). N, novel.
Fig. 5. The combination of BQCA with clozapine or aripiprazole, but not
with haloperidol, improves MK-801–induced spatial memory in C57Bl/6J
mice in the Y-maze test. (A) Mice pretreated with BQCA combined with
haloperidol showed no rescue of MK-801–induced memory disruption. (B
and C) In contrast, mice treated with combinations of BQCA (10 mg/kg,
s.c.) and clozapine (1 mg/kg), or BQCA (5 mg/kg, s.c.) and aripiprazole
(0.125 mg/kg), showed rescue of the MK-801 (0.15 mg/kg) memory
disruptive effect. *P , 0.05 (for difference between the novel and familiar
arms as an indication of normal memory function). Data are presented as
means 6 S.E.M. (n = 10–13 mice per group). N, novel.
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regions, such as the prefrontal cortex and hippocampus, have
received attention for their potential in rescuing cognitive
dysfunction (Bymaster et al., 2002; Shekhar et al., 2008;
Bridges et al., 2010; Barak and Weiner, 2011; Bolbecker and
Shekhar, 2012). In this study, we specifically focused on
NMDAR antagonism by MK-801 as a means of modeling
sensorimotor deficits and short-term memory disruption due
to glutamatergic hypofunction (Gilmour et al., 2012), as
opposed to pharmacological interventions such as amphet-
amine that model positive symptom domains but are more
limited for studying negative or cognitive domains (Young
et al., 2010; Katsnelson, 2014). For behavioral models, the PPI
test measures sensorimotor gating in the brain, as it is
impaired in patients with schizophrenia, and has been used
in animals to identify and understand antipsychotic efficacies
of clinically available drugs (Keith et al., 1991; Bakshi et al.,
1994; Swerdlow et al., 1994; Swerdlow and Geyer, 1998;
Cadenhead et al., 1999; Young et al., 2010; Moore et al.,
2013). TheY-maze test is a short-term spatialmemory paradigm
for assessing hippocampal-dependent memory function (Conrad
et al., 1996, 1997; Choy et al., 2008; Shipton et al., 2014), which is
highly vulnerable to pathologic factors such as stress (Heckers
et al., 1998; Harrison, 2004; Sweatt, 2004; van Erp et al., 2004,
2016; Tanskanen et al., 2005; Vakalopoulos, 2006; Velakoulis
et al., 2006; Choy et al., 2008) and is impaired from the earliest
stages of schizophrenia (Wood et al., 2002, 2003). Therefore,
the Y-maze test has potential to provide preclinical insights
into the effects of combining BQCA and antipsychotics on
brain regions affected along the pathologic trajectory of
schizophrenia (Heckers et al., 1998; Weinberger, 1999;
Lipska and Weinberger, 2002; Harrison, 2004; Sweatt, 2004;
van Erp et al., 2004; Harrison and Weinberger, 2005;
Tanskanen et al., 2005; Velakoulis et al., 2006)
In general, BQCA alone had minimal effects in both behav-
ioral models. With the exception of the highest dose of
clozapine (5 mg/kg), which also affected the animal startle
response, the doses of haloperidol, clozapine, and aripiprazole
used in this studywere insufficient to restore normal PPI after
MK-801 treatment, consistent with findings from previous
studies (Bakshi et al., 1994; Bast et al., 2000; Ishii et al., 2010).
However, it should be noted that this subeffective dosing was
necessary to reveal the effect of combination with BQCA.
Fig. 6. The enhancement of efficacy of clozapine by BQCA in reversing
PPI deficits is absent in M1 mAChR knockout mice. MK-801 (0.3 mg/kg)
induced PPI disruption in both M1
+/+ mice (top) and M1
2/2 mice (bottom).
Despite differences in the PPI profile between C57Bl/6J and M1
+/+ (C57Bl/
6N background) mice, an additive effect of BQCA (20 mg/kg, i.p.) and
clozapine (3 mg/kg) was still observed in the M1
+/+ mice but not in the M1
2/2
mice. The synergetic effect was particularly significant at pp6 (Table 3).
*P , 0.05 (for difference with MK-801 post hoc comparisons); ^P , 0.05
(for significantMK-801–induced disruption). Dataare presented asmeans6
S.E.M. (M1
+/+ vehicle and MK-801 controls, n = 15–16; M1
+/+ treatment
groups, n = 8–9; M1
2/2 vehicle and MK-801 controls, n = 13–15; and M1
2/2
treatment groups, n = 8).
TABLE 3
PPI measured with prepulses at 6, 12, and 18 db above the background in M1
+/+ and M1
2/2 (C57Bl/6 Ntac
background) mice, which received BQCA via the intraperitoneal route
Data are presented as means 6 S.E.M.
Group
PPI
pp6 pp12 pp18
%
M1
+/+ mice
Vehicle control 46.8 6 3.9 69.0 6 4.1 76.4 6 3.6
MK-801 0.9 6 8.6* 27.8 6 9.3* 45.1 6 7.1*
+ 1 mg/kg BQCA 22.4 6 6.1 28.1 6 8.4 35.0 6 10.7
+ 20 mg/kg BQCA 14.0 6 6.3 42.2 6 5.3 63.0 6 4.9
MK-801 + 3 mg/kg clozapine 10.9 6 9.6 39.8 6 9.4 58.3 6 6.1
+ 1 mg/kg BQCA 19.4 6 4.5 44.4 6 4.6 59.5 6 5.2
+ 20 mg/kg BQCA 34.7 6 5.0** 54.0 6 4.8 68.8 6 2.7
M1
2/2 mice
Vehicle control 35.4 6 4.0 65.7 6 2.4 75.5 6 2.4
MK-801 8.7 6 4.8* 41.9 6 4.8* 57.0 6 2.6*
+ 1 mg/kg BQCA 14.3 6 5.9 45.2 6 4.5 59.9 6 4.6
+ 20 mg/kg BQCA 17.4 6 4.2 47.3 6 4.6 59.1 6 3.2
MK-801 + 3 mg/kg clozapine 16.4 6 6.0 50.9 6 5.6 65.8 6 3.4
+ 1 mg/kg BQCA 16.7 6 5.7 46.7 6 4.9 58.0 6 4.8
+ 20 mg/kg BQCA 23.4 6 8.3 51.5 6 4.7 62.7 6 6.2
*P , 0.05 (versus vehicle control 2 MK-801 effect); **P , 0.05 (versus MK-801 control at the same prepulse).
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Lowering doses of antipsychotics also brings potential bene-
fits, because the side-effect burden would be lessened if
therapeutically effective lower doses were to be administered
clinically. The fact that coadministration of the M1 mAChR
PAM with each of the three classes of antipsychotic rescued
the disrupted PPI response indicates that sensorimotor gating
deficits can be particularly amenable to combination therapy,
even in the case of clozapine, which itself has affinity for the
M1 mAChR. Presumably, potentiation of endogenous ACh
affinity at this receptor by BQCA, however, would reduce M1
mAChR occupancy by clozapine (and its metabolites) in
preference for the full agonist, ACh. Importantly, we con-
firmed that the combined effect of BQCA and clozapine was
reproducible in the M1
1/1 mice but lost in the M1
2/2 mice,
despite differences in the overall PPI profile between the
C57Bl/6 substrains (Matsuo et al., 2010).
In addition to sensorimotor gating deficits, spatial memory
dysfunction, which is mostly associated with decline of
hippocampal function, has been commonly observed in pa-
tients with schizophrenia, even at early onset stages (Saykin
et al., 1994; Weinberger and Gallhofer, 1997; Heckers et al.,
1998; Wood et al., 2002; Bertolino et al., 2003; Egeland et al.,
2003; Brewer et al., 2005; Bartholomeusz et al., 2011).
In contrast with the PPI studies, the atypical antipsy-
chotics, clozapine and aripiprazole, but not haloperidol,
showed an enhancement of efficacy by BQCA in reversing
MK-801–induced spatial memory disruption in the Y-maze.
The hippocampus has a high expression ofM1mAChRs, which
are important for memory formation in rodents (Talts et al.,
1998; Anagnostaras et al., 2003; Lee andKesner, 2003; Newell
et al., 2007; Mauck et al., 2010; Peng et al., 2012). Indeed,
BQCA enhances baseline spatial and object recognition
memory in rodents (Chambon et al., 2011, 2012), reverses
scopolamine-disrupted fear and working memory, and re-
stores memory function in Tg2576 mice (Ma et al., 2009;
Shirey et al., 2009; Chambon et al., 2012). To our knowledge,
however, ours is the first study to extend these effects to rescue
of MK-801–induced memory impairments, albeit in the pres-
ence of a coadministered antipsychotic. Interestingly, another
recent study showed that a PAM of the M4 mAChR subtype
could rescue MK-801–induced impairments in a touchscreen-
based memory retrieval task (Bubser et al., 2014), and earlier
work established that the cholinesterase inhibitor, donepezil,
can also rescue MK-801–disrupted fear memory (Csernansky
et al., 2005).
In terms of the brain regions mediating the interactions
between the M1 mAChR PAM and antipsychotics in our
models, it is likely that cortical and striatal regions are
involved in the PPI effects, since they express the M1 mAChR
(Han et al., 2008; Ma et al., 2009; Peng et al., 2012) and have
been implicated in regulation of sensorimotor gating mecha-
nisms (Swerdlow et al., 1990, 2001; Geyer et al., 2001; Braff,
2010). Although the M1 mAChR is also found in the hippo-
campus, it is unlikely to be as important in the observed
effects, as MK-801–induced PPI disruption does not involve
this region and, if anything, cholinergic activation in the
hippocampus can itself lead to some PPI disruption (Caine
et al., 1991, 1992; Zhang et al., 2000). In contrast, the Y-maze
test is substantially hippocampal dependent (Conrad et al.,
1996, 2007; Choy et al., 2010; Shipton et al., 2014). Nonethe-
less, the possible involvement of cortical regions in both
behaviors should not be overlooked, as cortical, striatal, and
hippocampal networks play an important role in higher
cognitive function (Turnock and Becker, 2008; Pennartz et al.,
2011; Britt et al., 2012).
An area of ongoing discussion is the issue of whether “single-
target bullets” or “multifunction drugs” will lead to more
effective medications for schizophrenia (Pantelis and Barnes,
1996; Roth et al., 2004; Miyamoto et al., 2012). What remains
indisputable, however, is that schizophrenia is a disorder that
requires drugs capable of targetingmultiple symptomdomains,
in particular cognitive deficits. Moreover, the incidence of
adverse effects remains a major problem for patients undergo-
ing chronic treatment with existing antipsychotics (Nasrallah,
2008). Both of these issues may conceivably be addressed by
judicious combination therapies. For instance, although cloza-
pine was used as proof of concept in our study, it may not be
amenable for combination therapies in practice due to its
known on-target mAChR effects, whereas other atypical agents
(e.g., aripiprazole or risperidone, which have minimal mAChR
activity; Roth et al., 2004) may represent more appropriate
candidates. Furthermore, the addition of a highly selective
mAChRPAM (i.e., single-target bullet)may yield an increase in
symptom domain coverage together with an existing antipsy-
chotic (i.e., multifunction drug). Although these issues remain
speculative at this time, our study shows that we can observe
synergistic or additive efficacy in our models while essentially
retaining normal exploratory behaviors in the Y-maze test and
normal body reflex upon acoustic startle stimulation in the PPI
test. Thus, in addition to offering novel approaches to targeting
G protein–coupled receptors in a highly selective manner to
address unmet medical needs, allosteric modulators may
potentially allow extension of the clinical efficacy of existing
therapeutics and warrant further study in this regard.
Acknowledgments
The authors thank Dr. JürgenWess for providing M1
1/1 and M1
2/2
mice, Leigh Howard for maintaining the mouse colonies in-house, Dr.
Susan Charman for helpful discussions regarding mouse exposure
studies, and Drs. Jeremy Shonberg and Ben Capuano for synthesis of
clozapine and aripiprazole.
Authorship Contributions
Participated in research design: Choy, Shackleford, Malone, Lane,
Christopoulos.
Conducted experiments: Choy, Shackleford, Mistry, Patil, Scammells,
Lane.
Performed data analysis: Choy, Shackleford, Malone, Lane.
Wrote or contributed to the writing of the manuscript: Choy,
Shackleford, Malone, Mistry, Scammells, Langmead, Pantelis, Sexton,
Lane, Christopoulos.
References
Abdul-Ridha A, Lane JR, Mistry SN, López L, Sexton PM, Scammells PJ, Christopoulos
A, and Canals M (2014) Mechanistic insights into allosteric structure-function
relationships at the M1 muscarinic acetylcholine receptor. J Biol Chem 289:
33701–33711.
Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson
NM, and Silva AJ (2003) Selective cognitive dysfunction in acetylcholine M1
muscarinic receptor mutant mice. Nat Neurosci 6:51–58.
Bakshi VP, Swerdlow NR, and Geyer MA (1994) Clozapine antagonizes
phencyclidine-induced deficits in sensorimotor gating of the startle response. J
Pharmacol Exp Ther 271:787–794.
Barak S and Weiner I (2011) The M₁/M₄ preferring agonist xanomeline reverses
amphetamine-, MK801- and scopolamine-induced abnormalities of latent in-
hibition: putative efficacy against positive, negative and cognitive symptoms in
schizophrenia. Int J Neuropsychopharmacol 14:1233–1246.
Bartholomeusz CF, Proffitt TM, Savage G, Simpson L, Markulev C, Kerr M,
McConchie M, McGorry PD, Pantelis C, Berger GE, et al. (2011) Relational
memory in first episode psychosis: implications for progressive hippocampal dys-
function after illness onset. Aust N Z J Psychiatry 45:206–213.
362 Choy et al.
 at A
SPET Journals on O
ctober 13, 2016
jpet.aspetjournals.org
D
ow
nloaded from
 
Bast T, Zhang W, Feldon J, and White IM (2000) Effects of MK801 and neuroleptics
on prepulse inhibition: re-examination in two strains of rats. Pharmacol Biochem
Behav 67:647–658.
Bertolino A, Sciota D, Brudaglio F, Altamura M, Blasi G, Bellomo A, Antonucci N,
Callicott JH, Goldberg TE, Scarabino T, et al. (2003) Working memory deficits and
levels of N-acetylaspartate in patients with schizophreniform disorder. Am J
Psychiatry 160:483–489.
Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE,
Tollefson GD, Rasmussen K, Bymaster FP, et al. (1997) Effects of xanomeline, a
selective muscarinic receptor agonist, on cognitive function and behavioral symp-
toms in Alzheimer disease. Arch Neurol 54:465–473.
Bolbecker AR and Shekhar A (2012) Muscarinic agonists and antagonists in
schizophrenia: recent therapeutic advances and future directions. Handb Exp
Pharmacol 208:167–190.
Bora E, Yucel M, and Pantelis C (2009) Cognitive functioning in schizophrenia,
schizoaffective disorder and affective psychoses: meta-analytic study. Br J Psy-
chiatry 195:475–482.
Bradford AM, Savage KM, Jones DN, and Kalinichev M (2010) Validation and
pharmacological characterisation of MK-801-induced locomotor hyperactivity in
BALB/C mice as an assay for detection of novel antipsychotics. Psychopharma-
cology (Berl) 212:155–170.
Braff DL (2010) Prepulse inhibition of the startle reflex: a window on the brain in
schizophrenia. Curr Top Behav Neurosci 4:349–371.
Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, Yung AR,
Anderson VA, and McGorry PD (2005) Memory impairments identified in people at
ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psy-
chiatry 162:71–78.
Bridges TM, LeBois EP, Hopkins CR, Wood MR, Jones CK, Conn PJ, and Lindsley
CW (2010) The antipsychotic potential of muscarinic allosteric modulation. Drug
News Perspect 23:229–240.
Britt JP, Benaliouad F, McDevitt RA, Stuber GD, Wise RA, and Bonci A (2012)
Synaptic and behavioral profile of multiple glutamatergic inputs to the nucleus
accumbens. Neuron 76:790–803.
Bubeníková V, Votava M, Horácek J, Pálenícek T, and Dockery C (2005) The effect of
zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor
gating. Pharmacol Biochem Behav 80:591–596.
Bubser M, Bridges TM, Dencker D, Gould RW, Grannan M, Noetzel MJ, Lamsal A,
Niswender CM, Daniels JS, Poslusney MS, et al. (2014) Selective activation of M4
muscarinic acetylcholine receptors reverses MK-801-induced behavioral impair-
ments and enhances associative learning in rodents. ACS Chem Neurosci 5:
920–942.
Bymaster FP, Felder C, Ahmed S, and McKinzie D (2002) Muscarinic receptors as a
target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord 1:
163–181.
Bymaster FP, McKinzie DL, Felder CC, and Wess J (2003) Use of M1-M5 muscarinic
receptor knockout mice as novel tools to delineate the physiological roles of the
muscarinic cholinergic system. Neurochem Res 28:437–442.
Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman
MM, Lucaites VL, and Calligaro DO (1999) Antagonism by olanzapine of dopamine
D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors
in vitro. Schizophr Res 37:107–122.
Cadenhead KS, Carasso BS, Swerdlow NR, Geyer MA, and Braff DL (1999) Prepulse
inhibition and habituation of the startle response are stable neurobiological mea-
sures in a normal male population. Biol Psychiatry 45:360–364.
Caine SB, Geyer MA, and Swerdlow NR (1991) Carbachol infusion into the dentate
gyrus disrupts sensorimotor gating of startle in the rat. Psychopharmacology (Berl)
105:347–354.
Caine SB, Geyer MA, and Swerdlow NR (1992) Hippocampal modulation of acoustic
startle and prepulse inhibition in the rat. Pharmacol Biochem Behav 43:
1201–1208.
Canals M, Lane JR, Wen A, Scammells PJ, Sexton PM, and Christopoulos A (2012) A
Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor
(GPCR) allosteric modulation. J Biol Chem 287:650–659.
Chambon C, Jatzke C, Wegener N, Gravius A, and Danysz W (2012) Using cholin-
ergic M1 receptor positive allosteric modulators to improve memory via enhance-
ment of brain cholinergic communication. Eur J Pharmacol 697:73–80.
Chambon C, Wegener N, Gravius A, and Danysz W (2011) A new automated method
to assess the rat recognition memory: validation of the method. Behav Brain Res
222:151–157.
Choy KH, de Visser Y, Nichols NR, and van den Buuse M (2008) Combined neonatal
stress and young-adult glucocorticoid stimulation in rats reduce BDNF expression
in hippocampus: effects on learning and memory. Hippocampus 18:655–667.
Choy KH, Dean O, Berk M, Bush AI, and van den Buuse M (2010) Effects of N-acetyl-
cysteine treatment on glutathione depletion and a short-term spatial memory
deficit in 2-cyclohexene-1-one-treated rats. Eur J Pharmacol 649:224–228.
Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets
for drug discovery. Nat Rev Drug Discov 1:198–210.
Conn PJ, Lindsley CW, Meiler J, and Niswender CM (2014) Opportunities and
challenges in the discovery of allosteric modulators of GPCRs for treating CNS
disorders. Nat Rev Drug Discov 13:692–708.
Conn PJ, Tamminga C, Schoepp DD, and Lindsley C (2008) Schizophrenia: moving
beyond monoamine antagonists. Mol Interv 8:99–107.
Conrad CD, Galea LA, Kuroda Y, and McEwen BS (1996) Chronic stress impairs rat
spatial memory on the Y maze, and this effect is blocked by tianeptine pre-
treatment. Behav Neurosci 110:1321–1334.
Conrad CD, Lupien SJ, Thanasoulis LC, and McEwen BS (1997) The effects of type I
and type II corticosteroid receptor agonists on exploratory behavior and spatial
memory in the Y-maze. Brain Res 759:76–83.
Conrad CD, McLaughlin KJ, Harman JS, Foltz C, Wieczorek L, Lightner E,
and Wright RL (2007) Chronic glucocorticoids increase hippocampal vulnerability
to neurotoxicity under conditions that produce CA3 dendritic retraction but fail to
impair spatial recognition memory. J Neurosci 27:8278–8285.
Csernansky JG, Martin M, Shah R, Bertchume A, Colvin J, and Dong H (2005)
Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in
mice. Neuropsychopharmacology 30:2135–2143.
Cui YH, Zheng Y, Yang YP, Liu J, and Li J (2010) Effectiveness and tolerability of
aripiprazole in children and adolescents with Tourette’s disorder: a pilot study in
China. J Child Adolesc Psychopharmacol 20:291–298.
Dellu F, Mayo W, Cherkaoui J, Le Moal M, and Simon H (1992) A two-trial memory
task with automated recording: study in young and aged rats. Brain Res 588:
132–139.
Didriksen M, Kreilgaard M, and Arnt J (2006) Sertindole, in contrast to clozapine
and olanzapine, does not disrupt water maze performance after acute or chronic
treatment. Eur J Pharmacol 542:108–115.
Egeland J, Sundet K, Rund BR, Asbjørnsen A, Hugdahl K, Landrø NI, Lund A,
Roness A, and Stordal KI (2003) Sensitivity and specificity of memory dysfunction
in schizophrenia: a comparison with major depression. J Clin Exp Neuropsychol 25:
79–93.
Enomoto T, Ishibashi T, Tokuda K, Ishiyama T, Toma S, and Ito A (2008) Lurasidone
reverses MK-801-induced impairment of learning and memory in the Morris water
maze and radial-arm maze tests in rats. Behav Brain Res 186:197–207.
Galloway CR, Lebois EP, Shagarabi SL, Hernandez NA, and Manns JR (2014) Effects
of selective activation of M1 and M4 muscarinic receptors on object recognition
memory performance in rats. Pharmacology 93:57–64.
Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, and Calabrese JR (2008)
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizo-
phrenia: a systematic review. J Clin Psychopharmacol 28:203–209.
Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, and Tonegawa S
(2001) Hyperactivity, elevated dopaminergic transmission, and response to am-
phetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad
Sci USA 98:15312–15317.
Geyer MA, Krebs-Thomson K, Braff DL, and Swerdlow NR (2001) Pharmacological
studies of prepulse inhibition models of sensorimotor gating deficits in schizo-
phrenia: a decade in review. Psychopharmacology (Berl) 156:117–154.
Gilmour G, Dix S, Fellini L, Gastambide F, Plath N, Steckler T, Talpos J,
and Tricklebank M (2012) NMDA receptors, cognition and schizophrenia–testing
the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology
62:1401–1412.
Gordon JA (2010) Testing the glutamate hypothesis of schizophrenia. Nat Neurosci
13:2–4.
Gould RW, Dencker D, Grannan M, Bubser M, Zhan X, Wess J, Xiang Z, Locuson C,
Lindsley CW, Conn PJ, et al. (2015) Role for the M1 muscarinic acetylcholine
receptor in top-down cognitive processing using a touchscreen visual discrimina-
tion task in mice. ACS Chem Neurosci 6:1683–1695.
Gronier B, Perry KW, and Rasmussen K (2000) Activation of the mesocorticolimbic
dopaminergic system by stimulation of muscarinic cholinergic receptors in the
ventral tegmental area. Psychopharmacology (Berl) 147:347–355.
Grube BS, Bilder RM, and Goldman RS (1998) Meta-analysis of symptom factors in
schizophrenia. Schizophr Res 31:113–120.
Han M, Newell K, Zavitsanou K, Deng C, and Huang XF (2008) Effects of antipsy-
chotic medication on muscarinic M1 receptor mRNA expression in the rat brain. J
Neurosci Res 86:457–464.
Harrison PJ (2004) The hippocampus in schizophrenia: a review of the neuropatho-
logical evidence and its pathophysiological implications. Psychopharmacology
(Berl) 174:151–162.
Harrison PJ and Weinberger DR (2005) Schizophrenia genes, gene expression, and
neuropathology: on the matter of their convergence. Mol Psychiatry 10:40–68;
image 45.
Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC, Hoblyn J,
and Davis KL (1998) Symptoms, cognitive functioning, and adaptive skills in ge-
riatric patients with lifelong schizophrenia: a comparison across treatment sites.
Am J Psychiatry 155:1080–1086.
Heckers S, Rauch SL, Goff D, Savage CR, Schacter DL, Fischman AJ, and Alpert NM
(1998) Impaired recruitment of the hippocampus during conscious recollection in
schizophrenia. Nat Neurosci 1:318–323.
Heinrichs RW and Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: a
quantitative review of the evidence. Neuropsychology 12:426–445.
Ishii D, Matsuzawa D, Kanahara N, Matsuda S, Sutoh C, Ohtsuka H, Nakazawa K,
Kohno M, Hashimoto K, Iyo M, et al. (2010) Effects of aripiprazole on MK-801-
induced prepulse inhibition deficits and mitogen-activated protein kinase signal
transduction pathway. Neurosci Lett 471:53–57.
Javitt DC (2007) Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate
receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78:69–108.
Javitt DC and Zukin SR (1991) Recent advances in the phencyclidine model of
schizophrenia. Am J Psychiatry 148:1301–1308.
Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges
TM, Kennedy JP, Bradley SR, et al. (2008) Novel selective allosteric activator of the
M1 muscarinic acetylcholine receptor regulates amyloid processing and produces
antipsychotic-like activity in rats. J Neurosci 28:10422–10433.
Kandel ER (2000) Disorders of thought and volition: schizophrenia, in Principles of
Neural Science (Kandel ER, Schwartz JH, and Jessell TM eds) p 1414, McGraw-
Hill, New York.
Kapur S, VanderSpek SC, Brownlee BA, and Nobrega JN (2003) Antipsychotic
dosing in preclinical models is often unrepresentative of the clinical condition: a
suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:
625–631.
Katsnelson A (2014) Drug development: The modelling challenge. Nature 508:S8–S9.
Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY,
Green MF, Capuano G, Stroup TS, et al.; CATIE Investigators; Neurocognitive
Working Group (2007) Neurocognitive effects of antipsychotic medications in
M1 Positive Allosteric Modulation Improves Antipsychotic Efficacy 363
 at A
SPET Journals on O
ctober 13, 2016
jpet.aspetjournals.org
D
ow
nloaded from
 
patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:
633–647.
Keith VA, Mansbach RS, and Geyer MA (1991) Failure of haloperidol to block the
effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol
Psychiatry 30:557–566.
Kruse AC, Kobilka BK, Gautam D, Sexton PM, Christopoulos A, and Wess J (2014)
Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat
Rev Drug Discov 13:549–560.
Langmead CJ, Watson J, and Reavill C (2008) Muscarinic acetylcholine receptors as
CNS drug targets. Pharmacol Ther 117:232–243.
Lee I and Kesner RP (2003) Time-dependent relationship between the dorsal
hippocampus and the prefrontal cortex in spatial memory. J Neurosci 23:
1517–1523.
Lester DB, Rogers TD, and Blaha CD (2010) Acetylcholine-dopamine interactions in
the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16:
137–162.
Lieberman JA, Javitch JA, and Moore H (2008) Cholinergic agonists as novel
treatments for schizophrenia: the promise of rational drug development for psy-
chiatry. Am J Psychiatry 165:931–936.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO,
Keefe RS, Davis SM, Davis CE, Lebowitz BD, et al.; Clinical Antipsychotic Trials
of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of an-
tipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:
1209–1223.
Lipska BK and Weinberger DR (2002) A neurodevelopmental model of schizophrenia:
neonatal disconnection of the hippocampus. Neurotox Res 4:469–475.
Long LE, Malone DT, and Taylor DA (2006) Cannabidiol reverses MK-801-induced
disruption of prepulse inhibition in mice. Neuropsychopharmacology 31:
795–803.
Lublin H, Eberhard J, and Levander S (2005) Current therapy issues and unmet
clinical needs in the treatment of schizophrenia: a review of the new generation
antipsychotics. Int Clin Psychopharmacol 20:183–198.
Ma L, Seager MA, Wittmann M, Jacobson M, Bickel D, Burno M, Jones K, Graufelds
VK, Xu G, Pearson M, et al. (2009) Selective activation of the M1 muscarinic
acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci USA
106:15950–15955.
Mansbach RS, Geyer MA, and Braff DL (1988) Dopaminergic stimulation disrupts
sensorimotor gating in the rat. Psychopharmacology (Berl) 94:507–514.
Matsuo N, Takao K, Nakanishi K, Yamasaki N, Tanda K, and Miyakawa T (2010)
Behavioral profiles of three C57BL/6 substrains. Front Behav Neurosci 4:29.
Mauck B, Lucot JB, Paton S, and Grubbs RD (2010) Cholinesterase inhibitors and
stress: effects on brain muscarinic receptor density in mice. Neurotoxicology 31:
461–467.
Miyamoto S, Duncan GE, Marx CE, and Lieberman JA (2005) Treatments for
schizophrenia: a critical review of pharmacology and mechanisms of action of an-
tipsychotic drugs. Mol Psychiatry 10:79–104.
Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, and Lieberman JA (2012)
Pharmacological treatment of schizophrenia: a critical review of the pharmacology
and clinical effects of current and future therapeutic agents. Mol Psychiatry 17:
1206–1227.
MoghaddamB and Javitt D (2012) From revolution to evolution: the glutamate hypothesis
of schizophrenia and its implication for treatment. Neuropsychopharmacology 37:4–15.
Moore H, Geyer MA, Carter CS, and Barch DM (2013) Harnessing cognitive neuro-
science to develop new treatments for improving cognition in schizophrenia:
CNTRICS selected cognitive paradigms for animal models. Neurosci Biobehav Rev
37 (Pt B):2087–2091.
Murray JB (2002) Phencyclidine (PCP): a dangerous drug, but useful in schizo-
phrenia research. J Psychol 136:319–327.
Mutlu O, Ulak G, Celikyurt IK, Akar FY, and Erden F (2011) Effects of olanzapine,
sertindole and clozapine on learning and memory in the Morris water maze test in
naive and MK-801-treated mice. Pharmacol Biochem Behav 98:398–404.
Nasrallah HA (2008) Atypical antipsychotic-induced metabolic side effects: insights
from receptor-binding profiles. Mol Psychiatry 13:27–35.
Natesan S, Reckless GE, Barlow KB, Nobrega JN, and Kapur S (2011) Partial ago-
nists in schizophrenia–why some work and others do not: insights from preclinical
animal models. Int J Neuropsychopharmacol 14:1165–1178.
Newell KA, Zavitsanou K, and Huang XF (2007) Opposing short- and long-term
effects on muscarinic M1/4 receptor binding following chronic phencyclidine
treatment. J Neurosci Res 85:1358–1363.
Nicolazzo JA, Steuten JA, Charman SA, Taylor N, Davies PJ, and Petrou S (2010)
Brain uptake of diazepam and phenytoin in a genetic animal model of absence
epilepsy. Clin Exp Pharmacol Physiol 37:647–649.
Nilsson M, Hansson S, Carlsson A, and Carlsson ML (2007) Differential effects of the
N-methyl-d-aspartate receptor antagonist MK-801 on different stages of object
recognition memory in mice. Neuroscience 149:123–130.
Owen MJ, Sawa A, and Mortensen PB (2016) Schizophrenia. Lancet 388:86–97.
Pantelis C, Barber FZ, Barnes TR, Nelson HE, Owen AM, and Robbins TW (1999)
Comparison of set-shifting ability in patients with chronic schizophrenia and
frontal lobe damage. Schizophr Res 37:251–270.
Pantelis C and Barnes TR (1996) Drug strategies and treatment-resistant schizo-
phrenia. Aust N Z J Psychiatry 30:20–37.
Pantelis C, Barnes TR, Nelson HE, Tanner S, Weatherley L, Owen AM, and Robbins
TW (1997) Frontal-striatal cognitive deficits in patients with chronic schizophre-
nia. Brain 120:1823–1843.
Pantelis C and Lambert TJ (2003) Managing patients with “treatment-resistant”
schizophrenia. Med J Aust 178 (Suppl):S62–S66.
Pantelis C, Stuart GW, Nelson HE, Robbins TW, and Barnes TR (2001) Spatial
working memory deficits in schizophrenia: relationship with tardive dyskinesia
and negative symptoms. Am J Psychiatry 158:1276–1285.
Park SJ, Lee Y, Oh HK, Lee HE, Lee Y, Ko SY, Kim B, Cheong JH, Shin CY, and Ryu
JH (2014) Oleanolic acid attenuates MK-801-induced schizophrenia-like behaviors
in mice. Neuropharmacology 86:49–56.
Peng S, Zhang Y, Li GJ, Zhang DX, Sun DP, and Fang Q (2012) The effect of sevo-
flurane on the expression of M1 acetylcholine receptor in the hippocampus and
cognitive function of aged rats. Mol Cell Biochem 361:229–233.
Pennartz CM, Ito R, Verschure PF, Battaglia FP, and Robbins TW (2011) The
hippocampal-striatal axis in learning, prediction and goal-directed behavior.
Trends Neurosci 34:548–559.
Porter AC, Bymaster FP, DeLapp NW, Yamada M, Wess J, Hamilton SE, Nathanson
NM, and Felder CC (2002) M1 muscarinic receptor signaling in mouse hippo-
campus and cortex. Brain Res 944:82–89.
Roth BL, Sheffler DJ, and Kroeze WK (2004) Magic shotguns versus magic bullets:
selectively non-selective drugs for mood disorders and schizophrenia.Nat Rev Drug
Discov 3:353–359.
Rujescu D, Bender A, Keck M, Hartmann AM, Ohl F, Raeder H, Giegling I,
Genius J, McCarley RW, Möller HJ, et al. (2006) A pharmacological model for
psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular,
cellular, functional and behavioral abnormalities. Biol Psychiatry 59:
721–729.
Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock
BG, Watanabe K, Mimura M, et al. (2013) Dopamine D2 receptor occupancy and
cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull 39:
564–574.
Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, and Gur RC
(1994) Neuropsychological deficits in neuroleptic naive patients with first-episode
schizophrenia. Arch Gen Psychiatry 51:124–131.
Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster
FP, McKinzie DL, and Felder CC (2008) Selective muscarinic receptor agonist
xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165:
1033–1039.
Shipton OA, El-Gaby M, Apergis-Schoute J, Deisseroth K, Bannerman DM, Paulsen
O, and Kohl MM (2014) Left-right dissociation of hippocampal memory processes in
mice. Proc Natl Acad Sci USA 111:15238–15243.
Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, Jadhav SB,
Menon UN, Xiang Z, Watson ML, et al. (2009) A selective allosteric potentiator of
the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal
cortical neurons and restores impairments in reversal learning. J Neurosci 29:
14271–14286.
Speller JC, Barnes TR, Curson DA, Pantelis C, and Alberts JL (1997) One-year, low-
dose neuroleptic study of in-patients with chronic schizophrenia characterised by
persistent negative symptoms. Amisulpride v. haloperidol. Br J Psychiatry 171:
564–568.
Stone JM, Morrison PD, and Pilowsky LS (2007) Glutamate and dopamine dysregu-
lation in schizophrenia–a synthesis and selective review. J Psychopharmacol 21:
440–452.
Suratman S, Leach K, Sexton P, Felder C, Loiacono R, and Christopoulos A (2011)
Impact of species variability and ‘probe-dependence’ on the detection and in vivo
validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. Br
J Pharmacol 162:1659–1670.
Sweatt JD (2004) Hippocampal function in cognition. Psychopharmacology (Berl)
174:99–110.
Swerdlow NR, Braff DL, and Geyer MA (1990) GABAergic projection from nucleus
accumbens to ventral pallidum mediates dopamine-induced sensorimotor gating
deficits of acoustic startle in rats. Brain Res 532:146–150.
Swerdlow NR, Braff DL, Taaid N, and Geyer MA (1994) Assessing the validity of an
animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen
Psychiatry 51:139–154.
Swerdlow NR and Geyer MA (1998) Using an animal model of deficient sensorimotor
gating to study the pathophysiology and new treatments of schizophrenia. Schiz-
ophr Bull 24:285–301.
Swerdlow NR, Geyer MA, and Braff DL (2001) Neural circuit regulation of prepulse
inhibition of startle in the rat: current knowledge and future challenges. Psycho-
pharmacology (Berl) 156:194–215.
Talts U, Talts JF, and Eriksson P (1998) Differential expression of muscarinic
subtype mRNAs after exposure to neurotoxic pesticides. Neurobiol Aging 19:
553–559.
Tanskanen P, Veijola JM, Piippo UK, Haapea M, Miettunen JA, Pyhtinen J,
Bullmore ET, Jones PB, and Isohanni MK (2005) Hippocampus and amygdala
volumes in schizophrenia and other psychoses in the Northern Finland
1966 birth cohort. Schizophr Res 75:283–294.
Thal DM, Sun B, Feng D, Nawaratne V, Leach K, Felder CC, Bures MG, Evans DA,
Weis WI, Bachhawat P, et al. (2016) Crystal structures of the M1 and M4 mus-
carinic acetylcholine receptors. Nature 531:335–340.
Thomsen M, Wess J, Fulton BS, Fink-Jensen A, and Caine SB (2010) Modulation of
prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice.
Psychopharmacology (Berl) 208:401–416.
Turnock M and Becker S (2008) A neural network model of hippocampal-
striatal-prefrontal interactions in contextual conditioning. Brain Res 1202:
87–98.
Vakalopoulos C (2006) Neuropharmacology of cognition and memory: a unifying
theory of neuromodulator imbalance in psychiatry and amnesia. Med Hypotheses
66:394–431.
van der Staay FJ, Rutten K, Erb C, and Blokland A (2011) Effects of the cognition
impairer MK-801 on learning and memory in mice and rats. Behav Brain Res 220:
215–229.
van Erp TG, Hibar DP, Rasmussen JM, Glahn DC, Pearlson GD, Andreassen OA,
Agartz I, Westlye LT, Haukvik UK, Dale AM, et al. (2016) Subcortical brain volume
abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls
via the ENIGMA consortium. Mol Psychiatry 21:547–553.
364 Choy et al.
 at A
SPET Journals on O
ctober 13, 2016
jpet.aspetjournals.org
D
ow
nloaded from
 
van Erp TG, Saleh PA, Huttunen M, Lönnqvist J, Kaprio J, Salonen O, Valanne L,
Poutanen VP, Standertskjöld-Nordenstam CG, and Cannon TD (2004) Hippocampal
volumes in schizophrenic twins. Arch Gen Psychiatry 61:346–353.
Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A, Phillips L, Smith D, Brewer
W, Proffitt T, Desmond P, et al. (2006) Hippocampal and amygdala volumes
according to psychosis stage and diagnosis: a magnetic resonance imaging study of
chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals.
Arch Gen Psychiatry 63:139–149.
Weinberger DR (1999) Cell biology of the hippocampal formation in schizophrenia.
Biol Psychiatry 45:395–402.
Weinberger DR and Gallhofer B (1997) Cognitive function in schizophrenia. Int Clin
Psychopharmacol 12 (Suppl 4):S29–S36.
Wood MD, Murkitt KL, Ho M, Watson JM, Brown F, Hunter AJ, and Middlemiss DN
(1999) Functional comparison of muscarinic partial agonists at muscarinic receptor
subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. Br J Pharmacol
126:1620–1624.
Wood SJ, Pantelis C, Proffitt T, Phillips LJ, Stuart GW, Buchanan JA, Mahony K,
Brewer W, Smith DJ, and McGorry PD (2003) Spatial working memory ability is a
marker of risk-for-psychosis. Psychol Med 33:1239–1247.
Wood SJ, Proffitt T, Mahony K, Smith DJ, Buchanan JA, Brewer W, Stuart GW,
Velakoulis D, McGorry PD, and Pantelis C (2002) Visuospatial memory and
learning in first-episode schizophreniform psychosis and established schizophrenia:
a functional correlate of hippocampal pathology? Psychol Med 32:429–438.
Yee BK, Chang T, Pietropaolo S, and Feldon J (2005) The expression of prepulse
inhibition of the acoustic startle reflex as a function of three pulse stimulus in-
tensities, three prepulse stimulus intensities, and three levels of startle re-
sponsiveness in C57BL6/J mice. Behav Brain Res 163:265–276.
Young JW, Zhou X, and Geyer MA (2010) Animal models of schizophrenia. Curr Top
Behav Neurosci 4:391–433.
Zhang WN, Bast T, and Feldon J (2000) Microinfusion of the non-competitive
N-methyl-D-aspartate receptor antagonist MK-801 (dizocilpine) into the dorsal
hippocampus of Wistar rats does not affect latent inhibition and prepulse in-
hibition, but increases startle reaction and locomotor activity. Neuroscience 101:
589–599.
Address correspondence to: Arthur Christopoulos or J. Robert Lane, Drug
Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash
University, 399 Royal Parade, Parkville, VIC 3052, Australia. E-mail: arthur.
christopoulos@monash.edu or rob.lane@monash.edu
M1 Positive Allosteric Modulation Improves Antipsychotic Efficacy 365
 at A
SPET Journals on O
ctober 13, 2016
jpet.aspetjournals.org
D
ow
nloaded from
 
JPET 235788 
1 
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Title:  Positive allosteric modulation of the muscarinic M1 receptor improves efficacy of 3 
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 5 
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Supplemental Fig.1 1 
 2 
Startle amplitude measured at pulse alone (p100, 110 and 120) during the PPI test 3 
remained unaffected by drug pretreatment, except mice that were treated by 20 mg/kg 4 
(s.c.) of BQCA and MK-801 (0.3 mg/kg). In particular, the higher startle amplitude is 5 
observed in tested mice measured at 110 and 120db stimulus (top panel).  6 
Data are mean ± SEM, * p < 0.05 vs MK-801 control, and # p < 0.05 vs vehicle control (-----). 7 
  8 
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Supplemental Fig. 2. 3 
PPI measured at p100 and p110 exhibited a similar effect as observed at p120. As 4 
mentioned in Materials and Methods, mice were tested in PPI of startle elicited by acoustic 5 
stimulus of 100, 110 and 120db, and prepulses. PPI measured at 120db is presented in the 6 
main text. PPI measured at p100 and p110 either shared a similar reversal seen in p120 or a 7 
trend of reversal, by combination of BQCA and antipsychotics.  8 
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Data are mean ± SEM, ^ p < 0.05 for difference between vehicle vs MK-801 controls, as 1 
indication of PPI disruption by MK-801; * p < 0.05 for difference between groups vs. MK-2 
801 control for a significant reversal of PPI disruption.   3 
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Supplemental Fig. 3. 3 
 4 
Memory function was not affected by pretreatment of BQCA alone, or combined BQCA 5 
and antipsychotics treatment, in mice without MK-801 treatment, whereas C57Bl/6J 6 
mice received BQCA (10 mg/kg s.c.) and clozapine (1 mg/kg), or aripiprazole (0.25 mg/kg) 7 
exhibited insufficient exploratory activity, and therefore excluded.  8 
* p < 0.05 for difference between novel and familiar arm as an indication of normal memory 9 
function.  10 
 11 
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Supplemental Fig 4.  6 
 7 
Assessment of BQCA exposure in mouse brain in the absence or presence of 8 
antipsychotics. (a) Experiment 1: Unbound concentrations (Cunbound in nM) of BQCA in 9 
brains of C57Bl/6J mice after s.c. (Suspensions in 50% Pharmasolve® based vehicle) or i.p. 10 
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(Solutions in 15% DMSO based vehicle) injection. I.p. injection of BQCA resulted in a 1 
higher drug delivery to the brain than s.c. injection. (b) Experiment 2: Cunbound of BQCA in 2 
M1+/+ and M1-/- mice (C57Bl/6N background) compared to C57Bl/6J mice, suggests that 3 
BQCA brain exposure was lower in the C57Bl/6N mice than C57Bl/6J mice, and that there 4 
was no difference between the genotypes (M1+/+ vs. M1-/-). (c) Experiment 3: Cunbound of 5 
BQCA in brain was assessed in C57Bl/6J mice after s.c. injection of BQCA (20 mg/kg), with 6 
or without coadministration of haloperidol (0.25 mg/kg i.p.), clozapine (2 mg/kg i.p.) or 7 
aripiprazole (top left graph). Ctotal of the antipsychotics (haloperidol, clozapine or aripiprazole) 8 
in brain was also assessed with or without coadministration of BQCA (20 mg/kg s.c.) (top 9 
right and bottom graphs). There was no enhancement of brain exposure of BQCA or 10 
antipsychotics when mice were dosed with both compounds. 11 
  12 
Cunbound was calculated as Ctotal * fu using published fu values of 0.126 in brain, respectively 13 
(Gould et al., 2015). Each value represents the mean within the range of data of n = 2-3 14 
animals per group.  15 
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Supplemental Fig. 5. 3 
 4 
Reversal of disrupted PPI induced by MK-801 in C57Bl/6J mice receiving BQCA via i.p. 5 
administration using a lower dosing range, as BQCA administrated via .i.p. route (DMSO 6 
containing vehicle) allowed a higher brain exposure compared to s.c. route. There was a 7 
similar Cunbound (in nM) of BQCA in the brain observed between BQCA administrated via i.p. 8 
and s.c. (39.1 ± 4.6 nM and 36.0 ± 4.5 nM respectively). Furthermore, a high dose of BQCA 9 
via i.p. (20 mg/kg) also produced a similar reversal effect on MK-801 treatment.   10 
 11 
Methods and data analysis: A separated cohort of C57Bl/6J received BQCA via i.p. route, 12 
together with vehicle and MK-801 alone controls. For data analysis, this PPI data was 13 
combined with data obtained from BQCA (s.c.) + clozapine cohort (Fig. 3b). The PPI% of 14 
both vehicle groups were approximately the same: BQCA s.c. cohort = 36.7 ± 2.5% and 15 
BQCA i.p. cohort = 36.9 ± 3.2%. ANOVA test were performed on the combined PPI data. 16 
BQCA (p < 0.001), clozapine (p = 0.022) and MK-801 (p < 0.001) effects were found, and 17 
then followed with Tukey’s post hoc comparisons, where ^ p < 0.05 for significant PPI 18 
disruptive effect of MK-801, and * p < 0.05 for difference with MK-801.  19 
 20 
